MetaADEDB 2.0 @ LMMD
Pyridostigmine Bromide
(VNYBTNPBYXSMOO-UHFFFAOYSA-M)
Structure
SMILES
C[n+]1cccc(c1)OC(=O)N(C)C.[Br-]
Molecular Formula:
C9H13BrN2O2
Molecular Weight:
261.116
Log P:
-2.4245
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
0
TPSA:
33.42
CAS Number(s):
101-26-8
Synonym(s)
1.
Pyridostigmine Bromide
2.
Mestinon
3.
Pyridostigmine
4.
Bromide, Pyridostigmine
External Link(s)
MeSHD011729
PubChem Compound91696191
7550
ChEBI8666
CHEMBLCHEMBL812
KEGGdr:D00487
Therapeutic Target DatabaseD09KKU
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 28US FAERS
2Pharmaceutical product complaintFAERS: 26US FAERS
3AstheniaFAERS: 17US FAERS
4Product quality issueFAERS: 14US FAERS
5FatigueFAERS: 10US FAERS
6Myasthenia GravisFAERS: 9

View details

39182
745827
921089
2112245
3227809
3751350
6419855
6689658
7327092
7420683
7491061
7697959
9572258
17098697
17199845
17711430
18942252
 		CTD
US FAERS
7MalaiseFAERS: 8US FAERS
8Medication residue presentFAERS: 8US FAERS
9Drug exposure during pregnancyFAERS: 6US FAERS
10DysarthriaFAERS: 6US FAERS
11HypotensionFAERS: 6US FAERS
12Medication ErrorFAERS: 5US FAERS
13Product substitution issueFAERS: 5US FAERS
14BradycardiaFAERS: 4US FAERS
15DiplopiaFAERS: 4921089
3227809		CTD
US FAERS
16Drug dose omissionFAERS: 4US FAERS
17Nephrotic SyndromeFAERS: 4US FAERS
18Product taste abnormalFAERS: 4US FAERS
19Therapeutic response unexpected with drug substitutionFAERS: 4US FAERS
20Amniotic fluid volume increasedFAERS: 3US FAERS
21ChillsFAERS: 3US FAERS
22ChokingFAERS: 3US FAERS
23HeadacheFAERS: 3US FAERS
24HypersensitivityFAERS: 3US FAERS
25Incorrect dose administeredFAERS: 3US FAERS
26Mastication disorderFAERS: 3US FAERS
27No adverse eventFAERS: 3US FAERS
28Poor quality drug administeredFAERS: 3US FAERS
29Product friableFAERS: 3US FAERS
30Product physical issueFAERS: 3US FAERS
31Product size issueFAERS: 3US FAERS
32Respiratory FailureFAERS: 3US FAERS
33SomnolenceFAERS: 3US FAERS
34Suicide attemptFAERS: 3US FAERS
35TremorFAERS: 3US FAERS
36Wrong technique in product usage processFAERS: 3US FAERS
37Abdominal discomfortFAERS: 2US FAERS
38Accidental deathFAERS: 2US FAERS
39Back PainFAERS: 2US FAERS
40Cardiac ArrestFAERS: 2US FAERS
41Choking sensationFAERS: 2US FAERS
42Circumstance or information capable of leading to medication errorFAERS: 2US FAERS
43Dandy-Walker SyndromeFAERS: 2US FAERS
44Drug dispensing errorFAERS: 2US FAERS
45Drug effect incompleteFAERS: 2US FAERS
46Drug label confusionFAERS: 2US FAERS
47Expired product administeredFAERS: 2US FAERS
48Feeling abnormalFAERS: 2US FAERS
49FlushingFAERS: 2US FAERS
50IleusFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
51Mental impairmentFAERS: 2US FAERS
52Myasthenic SyndromeFAERS: 2US FAERS
53NauseaFAERS: 2US FAERS
54PregnancyFAERS: 2US FAERS
55Product use in unapproved indicationFAERS: 2US FAERS
56Serotonin SyndromeFAERS: 2US FAERS
57StuporFAERS: 2US FAERS
58TachycardiaFAERS: 2US FAERS
59Therapy cessationFAERS: 2US FAERS
60Thermal burnFAERS: 2US FAERS
61Unevaluable eventFAERS: 2US FAERS
62VomitingFAERS: 2US FAERS
63Abdominal PainFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
64Accidental exposureFAERS: 1US FAERS
65Accidental overdoseFAERS: 1US FAERS
66Acute kidney injuryFAERS: 1US FAERS
67Adverse eventFAERS: 1US FAERS
68AgitationFAERS: 1US FAERS
69AngerFAERS: 1US FAERS
70Angina PectorisFAERS: 1US FAERS
71AnxietyFAERS: 1US FAERS
72AphagiaFAERS: 1US FAERS
73AphasiaFAERS: 1US FAERS
74ArthralgiaFAERS: 1US FAERS
75AsthmaFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
76Atrial FibrillationFAERS: 1US FAERS
77Atrioventricular BlockFAERS: 117711430CTD
US FAERS
78BedriddenFAERS: 1US FAERS
79Blood glucose increasedFAERS: 1US FAERS
80BradyphreniaFAERS: 1US FAERS
81Brain HypoxiaFAERS: 1US FAERS
82Cerebrovascular accidentFAERS: 1US FAERS
83Chest PainFAERS: 1US FAERS
84Chest discomfortFAERS: 1US FAERS
85Congenital HydrocephalusFAERS: 1US FAERS
86Congenital cerebellar agenesisFAERS: 1US FAERS
87ConstipationFAERS: 1US FAERS
88DeliriumFAERS: 1US FAERS
89DementiaFAERS: 1US FAERS
90Disease ProgressionFAERS: 1US FAERS
91DroolingFAERS: 1US FAERS
92Drug abuseFAERS: 1US FAERS
93Drug-disease interactionFAERS: 1US FAERS
94DysgeusiaFAERS: 1US FAERS
95DysphoniaFAERS: 1US FAERS
96Ejection Fraction DecreasedFAERS: 1US FAERS
97Evans syndromeFAERS: 1US FAERS
98Facial ParesisFAERS: 1US FAERS
99Feeling jitteryFAERS: 1US FAERS
100Gait inabilityFAERS: 1US FAERS
101GastritisFAERS: 1US FAERS
102General physical health deteriorationFAERS: 1US FAERS
103Hallucinations, mixedFAERS: 1US FAERS
104HypokinesiaFAERS: 1US FAERS
105HypoventilationFAERS: 1US FAERS
106Inability to afford medicationFAERS: 1US FAERS
107Incorrect route of drug administrationFAERS: 1US FAERS
108Increased bronchial secretionFAERS: 1US FAERS
109Intentional misuseFAERS: 1US FAERS
110Intercepted medication errorFAERS: 1US FAERS
111Intermediate syndromeFAERS: 1US FAERS
112Intestinal PerforationFAERS: 1US FAERS
113Intestinal Pseudo-ObstructionFAERS: 1US FAERS
114Intestinal resectionFAERS: 1US FAERS
115Joint Range of Motion DecreasedFAERS: 1US FAERS
116Limb injuryFAERS: 1US FAERS
117Lip swellingFAERS: 1US FAERS
118Liver AbscessFAERS: 1US FAERS
119Mantle cell lymphomaFAERS: 1US FAERS
120Medication residueFAERS: 1US FAERS
121Muscle FatigueFAERS: 1US FAERS
122MyalgiaFAERS: 127058124CTD
US FAERS
123Myocardial InfarctionFAERS: 1US FAERS
124NasopharyngitisFAERS: 1US FAERS
125OverdoseFAERS: 1US FAERS
126PalpitationsFAERS: 1US FAERS
127PneumoniaFAERS: 1US FAERS
128Product availability issueFAERS: 1US FAERS
129Product container seal issueFAERS: 1US FAERS
130Product difficult to swallowFAERS: 1US FAERS
131Product dispensing errorFAERS: 1US FAERS
132Product label issueFAERS: 1US FAERS
133Product residue presentFAERS: 1US FAERS
134Product solubility abnormalFAERS: 1US FAERS
135Product used for unknown indicationFAERS: 1US FAERS
136PruritusFAERS: 1US FAERS
137Respiratory distressFAERS: 1US FAERS
138Skin UlcerFAERS: 1US FAERS
139Sleep TalkingFAERS: 1US FAERS
140SomnambulismFAERS: 1US FAERS
141Symptom recurrenceFAERS: 1US FAERS
142SyncopeFAERS: 117711430CTD
US FAERS
143Therapeutic product effect incompleteFAERS: 1US FAERS
144ThymectomyFAERS: 1US FAERS
145UnderweightFAERS: 1US FAERS
146Upper respiratory tract congestionFAERS: 1US FAERS
147Urinary IncontinenceFAERS: 1US FAERS
148UrticariaFAERS: 1US FAERS
149Ventricular FibrillationFAERS: 1US FAERS
150Weight decreasedFAERS: 1US FAERS
151muscle injuryFAERS: 1US FAERS
152Anemia, Pernicious17098697CTD
153Apnea31175885CTD
154Blepharoptosis921089
3227809
16816519		CTD
155Cognition Disorders25785457CTD
156Concomitant disease aggravatedCanada Vigilance: 1Canada Vigilance
157Cranial nerve diseases17710662CTD
158EcchymosisCanada Vigilance: 1Canada Vigilance
159Gliosis25785457CTD
160Intestinal Diseases29751049CTD
161Memory Disorders27984134CTD
162Mobility Limitation29803855CTD
163Motor Skills Disorders30682440CTD
164Myocardial Ischemia15367503CTD
165Neuromuscular Diseases2666960CTD
166Ophthalmoplegia16816519CTD
167Organophosphate poisoning30682440CTD
168Peripheral Nervous System Diseases17710662CTD
169Persian Gulf Syndrome

View details

21948870
25785457
27058124
27984134
28659758
29751049
29803855
30503814
 		CTD
170Poisoning20144889
30176331		CTD
171TinnitusCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120141

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.